

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

00786/246002

Serial No.

09/365,576

Applicant

David Moore et al.

Filing Date

August 2, 1999

Group

1043 1646

IDS Filed

November 8, 1999

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

CFR §1.98(b))

## U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
MDP	4,981,784	01/01/91	Evans et al.	<del>          </del>		

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
MDP	WO 88/03168	5/1988	PCT	<del>          </del>	<del>          </del>	
MDP	WO 90/07517	1/1989	PCT	<del>          </del>	<del>          </del>	

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

MDP	Amero et al., Mol. Endocrinol. 6:3-7, 1992
↑	Baes et al., Mol. Cell. Biol. 14:1544-1552, 1994
	Blumberg et al., Proc. Natl. Acad. Sci. USA 89:2321-2325, 1992
	Brent et al., Mol. Endocrinol. 3:1996-2004, 1989
	Bugge et al., EMBO J. 11:1409-1418, 1992
	Danielian et al., EMBO J. 11:1025-1033, 1992
	de The et al., Nature 343:177-180, 1990
MDP	Evans, Science 240:889-895, 1988


EXAMINER

MICHAEL PAK

DATE CONSIDERED

6/26/01

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) PATENT AND TRADEMARK OFFICE

Attorney Docket No. 00786/246002  
Serial No. 09/365,576  
Applicant David Moore et al.  
Filing Date August 2, 1999  
Group ~~1642~~-1646  
IDS Filed November 8, 1999

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 CFR §1.98(b))

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

MDP	Fields et al., Nature 340:245-246, 1989
↑	Giguere et al., Genes & Dev. 8:538-553, 1994
	Green et al., Nature 325:75-78, 1987
	Gyuris et al., Cell 75:791-803, 1993
	Issemann et al., Nature 347:645-650, 1990
	Laudet et al., EMBO J. 11:1003-1013, 1992
	Leid et al., Trends Biochem. Sci. 17:427-433, 1992
	Leid et al., Cell 68:377-395, 1992
	Leroy et al., EMBO J. 10:59-69, 1991
	Ma et al., Cell 51:113-119, 1987
	Mangelsdorf et al., Nature 345:224-229, 1990
	Mangelsdorf et al., Cell 66:555-561, 1991
MDP	Mangelsdorf et al., Genes & Dev. 6:329-344, 1992

EXAMINER MICHAEL PAK

DATE CONSIDERED 6/26/01

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) PATENT AND TRADEMARK OFFICE

Attorney Docket No. 00786/246002  
Serial No. 09/365,576  
Applicant David Moore et al.  
Filing Date August 2, 1999  
Group 4643-1646  
IDS Filed November 8, 1999

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 CFR §1.98(b))

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

MDF	Oro et al., Nature 347:298-301, 1990
↑	Riddilough et al., EMBO J. 6:3729-3734, 1987
	Seagraves et al., Genes & Dev. 4:204-219, 1990
	Song et al., Proc. Natl. Acad. Sci. USA 91:10809-10813, 1994
	Yang et al., Genomics 7:509-516, 1990
	Yu et al., Cell 67:1251-1266, 1991
	Zervos et al., Cell 72:223-232, 1993
	Zhang et al., Nature 358:587-591, 1992
	Thomas et al., Nature 362:471-475, 1993
	Bowie et al., Science 247:1307-1310, 1990
	Lee et al., Mol. Endocrinol. 8:1245-52, 1994
	Mangelsdorf et al., Cell 83:841-50, 1995
	Seol et al., Mol. Endocrinol. 9:72-85, 1995
↓	Darnell et al., Molecular Cell Biology, Scientific American Books, Inc., New York, p. 255, 1986
MDF	George et al., Macromolecular Sequencing and Synthesis, Alan R. Liss, Inc., New York, pp. 127-149, 1988

EXAMINER MICHAEL PAK

DATE CONSIDERED 6/26/01

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

Sheet 1 of 1

SUBSTITUTE PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/246002
		Serial No.	09/356,576
		Applicant	Moore et al.
		Filing Date	August 2, 1999
		Group	1646
(37 CFR §1.98(b))		IDS Filed	December 4, 2000

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

## U.S. PATENTS

RECEIVED

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

TECH CENTER 1600/2900

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

MDP	Hörlein et al., "Ligand-Independent Repression by the Thyroid Hormone Receptor Mediated by a Nuclear Receptor Co-Repressor," <i>Nature</i> 377:397-404 (1995).

EXAMINER MICHAEL PARK	DATE CONSIDERED 6/21/01
--------------------------	----------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.